Objective: A meta-analysis was carried out of published studies on the effect of the CYP3A5 6986A>G polymorphism in liver donors and transplant recipients on tacrolimus pharmacokinetics.
Methods: Cohort studies that evaluated the relationship between the CYP3A5 polymorphism in liver donors and transplant recipients and tacrolimus, trough blood concentration normalized for the daily dose (C) per kilogram body weight (D) (C/D, ng/ml/mg/kg/day) up to 1 year after transplantation, were included. Data were not restricted by patient age or the language or journal of publication. A literature search was conducted using the Cochrane Library, MEDLINE, EMBASE, and grey literature, and articles published up to 24 April 2013 were selected. Data were pooled (random-effects model), and the results were expressed as the mean difference of the corresponding C/D ratios and 95% confidence intervals.
Results: Six studies involving donor genotypes (254 patients) and four involving recipient genotypes (180 patients) were ultimately included. The meta-analysis showed the C/D ratio to be significantly higher in recipients with nonexpresser donor variants at all time points. In recipients, the variant did not influence the C/D ratio.
Conclusion: The presence of the CYP3A5 6986A>G polymorphism in the donor affects tacrolimus pharmacokinetics in the recipient, although only the evidence available for the first month after transplantation was of adequate quality for demonstrating a significant difference. The evidence provided here shows no effect of the recipient genotype; however, the quality of the evidence was low, thereby precluding the drawing of firm conclusions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FPC.0b013e3283642fb3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations Between CYP3A5 (c.6986A>G) Gene Polymorphism and Kidney Impairment in Hypertensive Adults Without Cystatin C Elevation.
Cardiovasc Toxicol
October 2024
Department of Endocrinology, The First Affiliated Hospital of Soochow University, Suzhou City, 215000, Jiangsu Province, People's Republic of China.
Objective: This study aimed to explore the potential role of CYP3A5 (c. 6986A>G) gene polymorphism in predicting kidney function impairment in patients with hypertension who did not have elevated serum cystatin C.
Methods: We recruited a group of patients with hypertension who did not have elevated cystatin C and analyzed the CYP3A5 (c.
Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
Genes (Basel)
April 2024
Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Academia de Inmunología, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Unlabelled: Tacrolimus (TAC) is an immunosuppressant drug that prevents organ rejection after transplantation. This drug is transported from cells via P-glycoprotein (ABCB1) and is a metabolic substrate for cytochrome P450 (CYP) 3A enzymes, particularly CYP3A4 and CYP3A5. Several single-nucleotide polymorphisms (SNPs) have been identified in the genes encoding , , and , including CYP3A4-392A/G (rs2740574), CYP3A5 6986A/G (rs776746), and ABCB1 3435C/T (rs1045642).
View Article and Find Full Text PDFThe effects of the CYP3A5*3 variant on tacrolimus pharmacokinetics and outcomes in Tunisian kidney transplant recipients.
Tunis Med
October 2023
Charles Nicolle hospital -Department of immunology, Research Laboratory of Immunology of Renal Transplantation and Immunopathology (LR03SP01), 1006 Tunis, Tunisia.
Article Synopsis
- Tacrolimus shows variability in how it works in different individuals and has a small window between effective and harmful doses, with ongoing debate about the effect of a specific genetic variant (CYP3A5 6986A>G) on this variability.
- A study on Tunisian kidney transplant recipients examined the effects of this SNP on tacrolimus levels, adverse drug reactions (ADRs), and kidney graft outcomes over five years.
- Results indicated that patients with the CYP3A5*3 variant had higher tacrolimus concentrations and more ADRs, but this genetic variant did not affect the success of the kidney transplant.
Association of , and Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.
Anticancer Res
April 2023
Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
Background/aim: Osimertinib is a key drug for treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Genetic differences may be associated to adverse events (AEs) induced by osimertinib. This retrospective observational multicenter study evaluated the association of genotypes, including STAT3 -1697C>G, CYP3A5 6986A>G, and ABCG2 421C>A, with the incidence of osimertinib-induced AEs in patients with EGFR mutation-positive NSCLC.
View Article and Find Full Text PDFInfluence of , polymorphisms and metabolism rate on tacrolimus exposure in renal post-transplant recipients.
Pharmacogenomics
December 2022
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, Anhui, 230001, P.R. China.
To investigate the influence of and polymorphisms on tarcolimus metabolism and renal function for renal transplantation recipients at a stable period. and polymorphisms, together with other clinical factors, were collected for 149 renal transplantation patients at postoperative stable period. Statistics analysis was performed to explore key factors affecting tarcolimus metabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!